Related Experiment Video
Updated: May 26, 2025
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
Published on: March 7, 2025
Non-small cell lung cancer and the tumor microenvironment: making headway from targeted therapies to advanced
Anna De Lucia1, Lucia Mazzotti1,2, Anna Gaimari1,2
1Advanced Cellular Therapies and Rare Tumors Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy.
Abstract:
Over the past decades, significant progress has been made in the understanding of non-small cell lung cancer (NSCLC) biology and tumor progression mechanisms, resulting in the development of novel strategies for early detection and wide-ranging care approaches. Since their introduction, over 20 years ago, targeted therapies with tyrosine kinase inhibitors (TKIs) have revolutionized the treatment landscape for NSCLC. Nowadays, targeted therapies remain the gold standard for many patients, but still they suffer from many adverse effects, including unexpected toxicity and intrinsic acquired resistance mutations, which lead to relapse. The adoption of immune checkpoint inhibitors (ICIs) in 2015, has offered exceptional survival benefits for patients without targetable alterations. Despite this notable progress, challenges remain, as not all patients respond favorably to ICIs, and resistance to therapy can develop over time. A crucial factor influencing clinical response to immunotherapy is the tumor microenvironment (TME). The TME is pivotal in orchestrating the interactions between neoplastic cells and the immune system, influencing tumor growth and treatment outcomes. In this review, we discuss how the understanding of this intricate relationship is crucial for the success of immunotherapy and survey the current state of immunotherapy intervention, with a focus on forthcoming and promising chimeric antigen receptor (CAR) T cell therapies in NSCLC. The TME sets major obstacles for CAR-T therapies, creating conditions that suppress the immune response, inducing T cell exhaustion. To enhance treatment efficacy, specific efforts associated with CAR-T cell therapy in NSCLC, should definitely focus TME-related immunosuppression and antigen escape mechanisms, by combining CAR-T cells with immune checkpoint blockades.
Insights
Advances in non-small cell lung cancer (NSCLC) treatments include targeted therapies and immunotherapies. Understanding the tumor microenvironment (TME) is key to overcoming resistance and improving chimeric antigen receptor (CAR) T cell therapy efficacy in NSCLC.
Area of Science:
- Oncology
- Immunology
- Cancer Therapeutics
Background:
- Non-small cell lung cancer (NSCLC) treatment has evolved with targeted therapies (tyrosine kinase inhibitors) and immunotherapies (immune checkpoint inhibitors).
- While effective, targeted therapies face challenges like toxicity and acquired resistance, while immunotherapies show variable response rates and potential for resistance.
- The tumor microenvironment (TME) significantly influences treatment response and tumor progression in NSCLC.
Purpose of the Study:
- To review the current understanding of the tumor microenvironment's role in NSCLC immunotherapy.
- To discuss the potential and challenges of chimeric antigen receptor (CAR) T cell therapies in NSCLC.
- To highlight strategies for enhancing CAR-T cell therapy efficacy by targeting TME-mediated immunosuppression.
Main Methods:
- Literature review of current research on NSCLC biology, targeted therapies, immunotherapies, and the tumor microenvironment.
- Analysis of the impact of the TME on the efficacy of immune checkpoint inhibitors and CAR-T cell therapies.
- Exploration of combination strategies, such as CAR-T cells with immune checkpoint blockade, to overcome TME-related resistance mechanisms.
Main Results:
- The TME presents significant obstacles to CAR-T cell therapy, including immune suppression and T cell exhaustion.
- Understanding TME-driven immunosuppression and antigen escape is crucial for successful immunotherapy in NSCLC.
- Combining CAR-T cell therapy with immune checkpoint blockade shows promise for overcoming TME-related resistance.
Conclusions:
- Targeted therapies and immunotherapies have transformed NSCLC treatment, but challenges like resistance persist.
- The TME is a critical determinant of immunotherapy success in NSCLC, impacting CAR-T cell therapy efficacy.
- Future strategies should focus on modulating the TME to enhance CAR-T cell therapy outcomes in NSCLC, potentially through combination approaches.
More Related Videos
09:15Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
07:55Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
Published on: January 17, 2025
Related Concept Videos
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:17The Tumor Microenvironment
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...